Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Advancing Cardio-Oncology in Asia

  • Choon Ta Ng (Department of Cardiovascular Medicine, Mayo Clinic Rochester) ;
  • Li Ling Tan (Department of Cardiology, National University Heart Centre Singapore) ;
  • Il Suk Sohn (Department of Cardiology, Kyung Hee University Hospital at Gangdong) ;
  • Hilda Gonzalez Bonilla (Department of Cardiovascular Medicine, Mayo Clinic Rochester) ;
  • Toru Oka (Onco-Cardiology Unit, Department of Internal Medicine, Saitama Cancer Center) ;
  • Teerapat Yinchoncharoen (Department of Cardiology, Ramathibodi Hospital) ;
  • Wei-Ting Chang (Division of Cardiology, Department of Internal Medicine, Chi-Mei Medical Center) ;
  • Jun Hua Chong (Department of Cardiology, National Heart Centre Singapore) ;
  • Maria Katrina Cruz Tan (Department of Cardiology, St. Luke's Medical Center) ;
  • Rochelle Regina Cruz (Department of Cardiology, Cardinal Santos Medical Center) ;
  • Astri Astuti (Department of Cardiology and Vascular Medicine, Hasan Sadikin General Hospital) ;
  • Vivek Agarwala (Department of Medical Oncology and Haemato-Oncology, Narayana Superspeciality Hospital and Cancer Institute) ;
  • Van Chien (Department of Cardiology, National Heart Institute) ;
  • Jong-Chan Youn (Seoul St. Mary's Hospital, Catholic Research Institute for Intractable Cardiovascular Disease, College of Medicine, The Catholic University of Korea) ;
  • Jieli Tong (Department of Cardiology, Tan Tock Seng Hospital) ;
  • Joerg Herrmann (Department of Cardiovascular Medicine, Mayo Clinic Rochester)
  • Received : 2022.09.09
  • Accepted : 2022.10.25
  • Published : 2023.02.01
Download PDF
⟨ Previous Next ⟩

Abstract

Cardio-oncology is an emerging multi-disciplinary field, which aims to reduce morbidity and mortality of cancer patients by preventing and managing cancer treatment-related cardiovascular toxicities. With the exponential growth in cancer and cardiovascular diseases in Asia, there is an emerging need for cardio-oncology awareness among physicians and country-specific cardio-oncology initiatives. In this state-of-the-art review, we sought to describe the burden of cancer and cardiovascular disease in Asia, a region with rich cultural and socio-economic diversity. From describing the uniqueness and challenges (such as socio-economic disparity, ethnical and racial diversity, and limited training opportunities) in establishing cardio-oncology in Asia, and outlining ways to overcome any barriers, this article aims to help advance the field of cardio-oncology in Asia.

Keywords

Acknowledgement

Joerg Herrmann received funding from the NIH/NCI (CA233601) and the Miami Heart Research Institute and the Mayo Cardiovascular Research Center and Center for Biomedical Discovery. The other authors received no financial support for the research, authorship, and/or publication of this article.

References

  1. Falzone L, Salomone S, Libra M. Evolution of cancer pharmacological treatments at the turn of the third millennium. Front Pharmacol 2018;9:1300.
  2. Alvarez-Cardona JA, Ray J, Carver J, et al. Cardio-oncology education and training: JACC Council perspectives. J Am Coll Cardiol 2020;76:2267-81.
  3. Shi S, Lv J, Chai R, et al. Opportunities and challenges in cardio-oncology: a bibliometric analysis from 2010 to 2022. Curr Probl Cardiol 2022;101227.
  4. Ritchie H, Spooner F, Roser M. Causes of death [Internet]. [place unknown]: Our World in Data; 2018 [cited 2022 August 5]. Available from: https://ourworldindata.org/causes-of-death.
  5. Zhao D. Epidemiological features of cardiovascular disease in Asia. JACC Asia 2021;1:1-13.
  6. Global Burden of Disease 2019 Cancer Collaboration, Kocarnik JM, Compton K, et al.; Cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the global burden of disease study 2019. JAMA Oncol 2022;8:420-44.
  7. Centers for Disease Control and Prevention, National Center for Health Statistics. About multiple cause of death, 1999-2020. CDC WONDER Online Database website [Internet]. Atlanta (GA): Centers for Disease Control and Prevention; 2022 [cited 2022 February 21]. Available from: https://wonder.cdc.gov/.
  8. Ng CJ, Teo CH, Abdullah N, Tan WP, Tan HM. Relationships between cancer pattern, country income and geographical region in Asia. BMC Cancer 2015;15:613. 
  9. World Health Organization. Global health estimates: life expectancy and leading causes of death and disability [Internet]. Geneva: World Health Organization; 2022 [cited 2022 February 8]. Available from: https://www.who.int/data/gho/data/themes/mortality-and-global-health-estimates.
  10. Cao M, Li H, Sun D, Chen W. Cancer burden of major cancers in China: a need for sustainable actions. Cancer Commun (Lond) 2020;40:205-10.
  11. Liu Y, Zhang YL, Liu JW, Fang FQ, Li JM, Xia YL. Emergence, development, and future of cardio-oncology in China. Chin Med J (Engl) 2018;131:2640-4.
  12. Oka T, Akazawa H, Sase K, Hatake K, Komuro I. Cardio-oncology in Japan. JACC CardioOncol 2020;2:815-8.
  13. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209-49.
  14. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin 2022;72:7-33.
  15. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts [Internet]. Bethesda (MD): National Cancer Institute; 2022 [cited 2022 July 21]. Available from: https://seer.cancer.gov.
  16. American Cancer Society. The Cancer Atlas [Internet]. Atlanta (GA): American Cancer Society; 2022 [cited 2022 July 11]. Available from: https://canceratlas.cancer.org.
  17. Institute for Health Metrics and Evaluation (IHME). Website of IHME [Internet]. Seattle (WA): Institute for Health Metrics and Evaluation; 2022 [cited 2022 July 7]. Available from: https://www.healthdata.org.
  18. Centers for Disease Control and Prevention, National Center for Health Statistics. Leading causes of death [Internet]. Atlanta (GA): Centers for Disease Control and Prevention; 2022 [cited 2022 July 29]. Available from: https://www.cdc.gov/nchs/fastats/leading-causes-of-death.htm.
  19. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Pineros M, Znaor A, Soerjomataram I, Bray F. Global Cancer Observatory: Cancer Today [Internet]. Lyon: International Agency for Research on Cancer; 2020 [cited 2022 August 10]. Available from: https://gco.iarc.fr/today.
  20. Kimura T. East meets West: ethnic differences in prostate cancer epidemiology between East Asians and Caucasians. Chin J Cancer 2012;31:421-9.
  21. Gilchrist SC, Barac A, Ades PA, et al. Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: a scientific statement from the American Heart Association. Circulation 2019;139:e997-1012.
  22. Kwan ML, Cheng RK, Iribarren C, et al. Risk of heart failure with preserved versus reduced ejection fraction in women with breast cancer. Breast Cancer Res Treat 2022;193:669-75.
  23. Paterson DI, Wiebe N, Cheung WY, et al. Incident cardiovascular disease among adults with cancer: a population-based cohort study. JACC CardioOncol 2022;4:85-94.
  24. Youn JC, Chung WB, Ezekowitz JA, et al. Cardiovascular disease burden in adult patients with cancer: an 11-year nationwide population-based cohort study. Int J Cardiol 2020;317:167-73.
  25. Strongman H, Gadd S, Matthews AA, et al. Does cardiovascular mortality overtake cancer mortality during cancer survivorship?: an English retrospective cohort study. JACC CardioOncol 2022;4:113-23.
  26. Agarwala V, Choudhary N, Gupta S. A risk-benefit assessment approach to selection of adjuvant chemotherapy in elderly patients with early breast cancer: a mini review. Indian J Med Paediatr Oncol 2017;38:526-34.
  27. Okura Y, Takayama T, Ozaki K, et al. Future projection of cancer patients with cardiovascular disease in Japan by the year 2039: a pilot study. Int J Clin Oncol 2019;24:983-94.
  28. Chongsuvivatwong V, Phua KH, Yap MT, et al. Health and health-care systems in southeast Asia: diversity and transitions. Lancet 2011;377:429-37.
  29. The World Bank. World Bank open data [Internet]. Washington, D.C.: The World Bank; 2022 [cited 2022 July 29]. Available from: https://data.worldbank.org/. 
  30. Rahman MM, Karan A, Rahman MS, et al. Progress toward universal health coverage: a comparative analysis in 5 South Asian countries. JAMA Intern Med 2017;177:1297-305.
  31. Ohman RE, Yang EH, Abel ML. Inequity in cardio-oncology: identifying disparities in cardiotoxicity and links to cardiac and cancer outcomes. J Am Heart Assoc 2021;10:e023852.
  32. Economic and Social Commission for Asia and the Pacific. Inequality in Asia and the Pacific [Internet]. Bangkok: Economic and Social Commission for Asia and the Pacific; 2022 [cited 2022 July 11]. https://www.unescap.org/sites/default/d8files/01ExecutiveSummary.pdf.
  33. Eniu A, Cherny NI, Bertram M, et al. Cancer medicines in Asia and Asia-Pacific: what is available, and is it effective enough? ESMO Open 2019;4:e000483.
  34. Goh BC, Lim JF. Cancer drugs in Asian populations: availability, accessibility, and affordability. Cancer J 2020;26:323-9.
  35. Leighl NB, Nirmalakumar S, Ezeife DA, Gyawali B. An arm and a leg: the rising cost of cancer drugs and impact on access. Am Soc Clin Oncol Educ Book 2021;41:1-12.
  36. IQVIA Institute. Global Oncology Trends 2022. Durham (NC): IQVIA Institute; 2022.
  37. Kimman M, Jan S, Yip CH, et al.; ACTION Study Group. Catastrophic health expenditure and 12-month mortality associated with cancer in Southeast Asia: results from a longitudinal study in eight countries. BMC Med 2015;13:190.
  38. Venkatakrishnan K, Burgess C, Gupta N, et al. Toward optimum benefit-risk and reduced access lag for cancer drugs in Asia: a global development framework guided by clinical pharmacology principles. Clin Transl Sci 2016;9:9-22.
  39. Frankart AJ, Nagarajan R, Pater L. The impact of proton therapy on cardiotoxicity following radiation treatment. J Thromb Thrombolysis 2021;51:877-83.
  40. Gupta M, Singh N, Verma S. South Asians and cardiovascular risk: what clinicians should know. Circulation 2006;113:e924-9.
  41. Kario K, Chen CH, Park S, et al. Consensus document on improving hypertension management in Asian patients, taking into account Asian characteristics. Hypertension 2018;71:375-82.
  42. Telli ML, Chang ET, Kurian AW, et al. Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. Breast Cancer Res Treat 2011;127:471-8.
  43. Zhou W, Christiani DC. East meets West: ethnic differences in epidemiology and clinical behaviors of lung cancer between East Asians and Caucasians. Chin J Cancer 2011;30:287-92.
  44. O'Donnell PH, Dolan ME. Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res 2009;15:4806-14.
  45. Hao W, Shi YY, Qin YN, et al. Cardioprotective effect of Chinese herbal medicine for anthracycline-induced cardiotoxicity in cancer patients: a meta-analysis of prospective studies. Medicine (Baltimore) 2022;101:e29691.
  46. Cheng RK. Developing a cardio-oncology program from an early career perspective: challenges faced and lessons learned [Internet]. Washington, D.C.: American College of Cardiology; 2018 [cited 2022 September 1]. Available from: https://www.acc.org/membership/sections-and-councils/imaging-section/section-updates/2018/01/03/22/05/developing-a-cardio-oncology-program-from-an-early-career-perspective-challenges-faced-and-lessons-learned.
  47. Bhatia N, Lenihan D, Sawyer DB, Lenneman CG. Getting the SCOOP-survey of cardiovascular outcomes from oncology patients during survivorship. Am J Med Sci 2016;351:570-5.
  48. Herrmann J, Loprinzi C, Ruddy K. Building a cardio-onco-hematology program. Curr Oncol Rep 2018;20:81. 
  49. Chang WT, Feng YH, Kuo YH, et al. The impact of a multidisciplinary cardio-oncology programme on cardiovascular outcomes in Taiwan. ESC Heart Fail 2020;7:2135-9.
  50. Pareek N, Cevallos J, Moliner P, et al. Activity and outcomes of a cardio-oncology service in the United Kingdom-a five-year experience. Eur J Heart Fail 2018;20:1721-31.
  51. International Cardio-Oncology Society. IC-OS Centers of excellence certification [Internet]. Tampa (FL): International Cardio-Oncology Society; 2022 [cited 2022 August 20]. Available from: https://ic-os.org/excellence-certification/.
  52. Lyon AR, Dent S, Stanway S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail 2020;22:1945-60.
  53. Hayek SS, Ganatra S, Lenneman C, et al. Preparing the cardiovascular workforce to care for oncology patients: JACC review topic of the week. J Am Coll Cardiol 2019;73:2226-35.
  54. Peng J, Rushton M, Johnson C, et al. An international survey of healthcare providers' knowledge of cardiac complications of cancer treatments. Cardiooncology 2019;5:12.
  55. Xia Y, Liu J. Working together to advance cardio-oncology in China. JACC CardioOncol 2020;2:144-5.
  56. Kim H, Chung WB, Cho KI, et al. Diagnosis, treatment, and prevention of cardiovascular toxicity related to anti-cancer treatment in clinical practice: an opinion paper from the Working Group on CardioOncology of the Korean Society of Echocardiography. J Cardiovasc Ultrasound 2018;26:1-25.
  57. Bhatt DL. Birth and maturation of cardio-oncology. JACC CardioOncol 2019;1:114-6.
  58. Yoon GJ, Telli ML, Kao DP, Matsuda KY, Carlson RW, Witteles RM. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally? J Am Coll Cardiol 2010;56:1644-50.
  59. Oren O, Neilan TG, Fradley MG, Bhatt DL. Cardiovascular safety assessment in cancer drug development. J Am Heart Assoc 2021;10:e024033.
  60. McCain K, Hardesty C, Wong A. Charting a course to remodel universal healthcare in the Asia-Pacific [Internet]. Cologny: World Economic Forum; 2021 [cited 2022 July 16]. Available from: https://www.weforum.org/agenda/2021/11/how-to-remodel-universal-healthcare-in-the-asia-pacific/.
  61. Khalid A. Expanding universal health coverage in Asia [Internet]. Tacoma (WA): The Borgen Project; 2015 [cited 2022 August 25]. Available from: https://borgenproject.org/universal-health-care-in-asia/.
  62. Lagomarsino G, Garabrant A, Adyas A, Muga R, Otoo N. Moving towards universal health coverage: health insurance reforms in nine developing countries in Africa and Asia. Lancet 2012;380:933-43.
  63. Addison D, Campbell CM, Guha A, Ghosh AK, Dent SF, Jneid H. Cardio-oncology in the era of the COVID-19 pandemic and beyond. J Am Heart Assoc 2020;9:e017787.
  64. Evans WK, Ashbury FD, Hogue GL, Smith A, Pun J. Implementing a regional oncology information system: approach and lessons learned. Curr Oncol 2014;21:224-33.
  65. Sadler D, Chaulagain C, Alvarado B, et al. Practical and cost-effective model to build and sustain a cardio-oncology program. Cardiooncology 2020;6:9.
  66. Herrmann J, Lenihan D, Armenian S, et al. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J 2022;43:280-99.
  67. Jahangir E. The need for precision cardio-oncology [Internet]. Washington, D.C.: American College of Cardiology; 2020 [cited 2022 August 2]. Available from: https://www.acc.org/latest-in-cardiology/articles/2020/09/21/19/13/the-need-for-precision-cardio-oncology.
  68. Rhee JW, Ky B, Armenian SH, Yancy CW, Wu JC. Primer on biomarker discovery in cardio-oncology: application of omics technologies. JACC CardioOncol 2020;2:379-84. 
  69. Gerik L. Cardio-oncology, then and now: an interview with Barry Trachtenberg. Methodist DeBakey Cardiovasc J 2019;15:e1-3.
  70. Dreyfuss AD, Bravo PE, Koumenis C, Ky B. Precision cardio-oncology. J Nucl Med 2019;60:443-50.
  71. Attia ZI, Kapa S, Lopez-Jimenez F, et al. Screening for cardiac contractile dysfunction using an artificial intelligence-enabled electrocardiogram. Nat Med 2019;25:70-4.
  72. Zhou Y, Hou Y, Hussain M, et al. Machine learning-based risk assessment for cancer therapy-related cardiac dysfunction in 4300 longitudinal oncology patients. J Am Heart Assoc 2020;9:e019628.
  73. Chaix MA, Parmar N, Kinnear C, et al. Machine learning identifies clinical and genetic factors associated with anthracycline cardiotoxicity in pediatric cancer survivors. JACC CardioOncol 2020;2:690-706.
  74. Sadler DB, Moudgil R, Arco T, et al. Abstract 11675: Global cardio oncology registry: structure for a multinational collaboration. Circulation 2021;144 Suppl 1: 11675.